WSJ: More on the NEJM/Merck Mess

Monday's Wall Street Journal will have an article (requires paid subscription) that suggests that one of Merck's chief defense witnesses in its Vioxx litigation -- Alice Reisin, a top Merck scientist -- may have been irreparably harmed by last week's NEJM editorial, in which the medical journal suggested scientific misconduct in the underreporting of known instances of myocardial infarctions among Vioxx users.  In Monday's print edition, look for "Top Merck Witness May Become Liability In New Vioxx Trials," by Heather Won Tesoriero & Barbara Martinez, Page B1.  [tm]